US Launches Section 301 Probe Into India: These Export-Heavy Stocks Face the Most Heat

The United States has launched a fresh Section 301 trade investigation targeting India and 15 other countries, reviving tariff pressure just as markets were digesting a separate headline: Trump's 50% tariff threat could affect Indian exports worth $48 billion. Separately, the $7 billion India-US auto parts trade is bracing for significant impact.

For retail investors, the question isn't whether tariffs will come — it's which companies have the most revenue at stake. We searched through thousands of company filings on the NSE to find out.

Pharma: The Biggest Dollar Earners

Sun Pharmaceutical Industries (SUNPHARMA) is India's most US-exposed pharma company by sheer scale. Per their Q3 FY25 quarterly results, US formulation sales hit US$ 1,457 million for the first nine months of FY25, growing 5.7% year-on-year. The company has 531 approved ANDAs (abbreviated new drug applications) with the US FDA, with another 104 awaiting approval. Sun Pharma's chairman noted that two businesses surpassed $1 billion in annual sales during FY24 — Global Specialty and Emerging Markets. Any tariff on pharma imports into the US would directly hit this revenue stream, though pharma has historically received exemptions given the essential nature of drug supplies. Dr. Reddy's Laboratories (DRREDDY) reported North America revenues of Rs. 30.6 billion in a single quarter, with year-on-year growth of 64%, driven by new product launches, volume increases, and favorable forex. For 9M FY25, Global Generics revenues reached Rs. 214.2 billion, up 16% YoY. North America remains the company's largest market. Their recently acquired Nicotine Replacement Therapy (NRT) portfolio added to growth, though underlying growth excluding NRT was still a solid 13% for 9M FY25. Alkem Laboratories (ALKEM) derives 22.7% of total sales from the US, per their Q2 FY24 quarterly results. US business sales hit Rs. 7,675 million that quarter, growing 27.1% year-on-year and 10.4% sequentially. For a mid-cap pharma company, that's a significant single-market concentration. Gland Pharma (GLAND), the Hyderabad-based injectable specialist, saw its US revenue contribution rise to 26% of total sales in Q3 FY25, up from 21% just two quarters earlier, per their quarterly results. PAT increased 7% YoY while PAT margin improved to 15%. However, the company has previously faced US inventory rationalization — FY23 revenue fell 18% partly due to customer destocking in the US market. Any tariff-driven price disruption could trigger a repeat.

Auto Components: The $7 Billion Vulnerability

Sundram Fasteners (SUNDRMFAST), a TVS Group company that makes powertrain components and fasteners for global automakers, reported export sales of Rs. 1,174.47 crores for the nine months ended December 2024, per their 9M FY25 quarterly results. That's roughly 30% of their standalone revenue of Rs. 3,855.75 crores. The company has built cutting-edge capabilities in forging, metal forming, and close-tolerance machining — capabilities that serve US OEMs directly. A 50% tariff on these components would either compress margins or force US buyers to find costlier alternatives. Schaeffler India (SCHAEFFLER), the bearings and automotive technology major, reported Exports and Others revenue of Rs. 8,303.6 crores for 9M FY23, per their quarterly results. Total revenue from operations stood at Rs. 68,674.2 crores, with segment profit of Rs. 10,879.3 crores. The company operates across Automotive Technologies, Automotive Aftermarket, and Industrial segments — all of which have export components vulnerable to trade barriers.

Metals: Hindalco's Novelis Exposure

Hindalco Industries (HINDALCO) is uniquely exposed through its US subsidiary Novelis, one of the world's largest aluminium flat-rolled products companies. Per their Q3 FY23 quarterly results, Novelis reported EBITDA of $341 million (down 33% YoY) on shipments of 908,000 tonnes. Novelis has over 45 US-based subsidiaries and joint operations. The aluminium industry body has already sought RoDTEP (Remission of Duties and Taxes on Exported Products) relief to stay competitive. Hindalco's India upstream business recorded record production of 335,000 tonnes in Q3 FY23 with EBITDA of Rs. 1,591 crores — but margins compressed to 19.8% from much higher levels, showing how sensitive the business is to pricing and cost pressures.

What Retail Investors Should Do

Don't panic-sell on headlines alone. Pharma has historically been exempt from US tariffs due to the essential nature of drug supplies — but this time the rhetoric is broader. Here's a practical framework:

1. Check your portfolio's US revenue concentration. If you hold multiple pharma or auto component stocks, your tariff exposure may be higher than you think. Sun Pharma, Dr. Reddy's, Alkem, and Gland Pharma collectively derive billions from the US.

2. Watch for pass-through ability. Companies like Sun Pharma with specialty drugs have more pricing power than generic manufacturers. Gland Pharma's injectable focus gives it some moat, but its US destocking history shows vulnerability.

3. Auto components are the most directly threatened. Unlike pharma, auto parts have no essential goods exemption history. Sundram Fasteners and Schaeffler's export revenues face genuine risk.

4. Hindalco is a two-sided bet. Novelis's US operations could benefit from tariffs on competing imports into the US, but any retaliatory tariffs on Indian aluminium exports would hurt the India upstream business.

5. Wait for clarity on the India-US interim trade deal. Reports suggest a deal is being negotiated before July — if tariffs get reduced to 15% as recent developments suggest, the worst-case scenario may not materialize.

The Section 301 probe is a negotiating tool as much as a trade weapon. But the filing data shows clearly: India's pharma and auto component sectors have built deep US revenue dependencies over the past decade. Investors holding these stocks should monitor trade negotiations closely in the weeks ahead.

Data sourced from company filings on NSE via Xaro.